cagrilintide semaglutide combination trial weight loss New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) https://nej.md/444aW7f Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) https://nej.md/4ehQwLk What Is the Potential Role

References Viana CM, Freire D, Abrantes P, Rocha J, Pereira P

Available Peptides & Administration Methods GHK-CU administered via subcutaneous injection Sermorelin administered via subcutaneous injection Tesamorelin administered via subcutaneous injection BPC-157 available as a subcutaneous injection or oral capsule During your consultation, our team will help determine the best peptide and delivery method for your needs

At InCare, we make this powerful therapy accessible, understandable, and tailored to each patients goals

One compound that has generated a significant amount of buzz, and an equal amount of controversy, is BPC-157

However, when paired with GLP-1 in dual agonists like tirzepatide, the combination works synergistically to suppress appetite and increase energy expenditure

In blood pressure studies, the peptide did not affect basal blood pressure but counteracted both L-NAME-induced hypertension and L-arginine-induced hypotension